BioSpace News Archive

RS BioTherapeutics, whose mission is to harness its strong and thorough understanding of the endocannabinoid system (ECS) to research, develop and commercialize interventions to address chronic and acute pulmonary (lung) inflammation-based diseases, is pleased to announce positive results from its proof-of-concept study for its first investigational compound, RSBT-001.

Amid rising concerns about a lack of testing to stop the spread of the monkeypox virus, Neelyx Labs, an independent diagnostics firm based in the Chicago area, announced they are now processing monkeypox PCR tests, with a capacity of 8,000 tests per day. Neelyx also delivers stat tests with a 1-hour turnaround using the XDiveTM ultrafast, real-time PCR instrument.

Oxurion NV a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders, announced participation in two upcoming conferences.

Quest Diagnostics (NYSE: DGX), the world’s leading provider of diagnostic information services, today released its 2021 Corporate Responsibility Report.

Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, announced the appointment of Steven W. Ryder, M.D. to its Board of Directors, effective July 11, 2022.

MAKO Medical Laboratories , a national reference laboratory, today announced it has validated a PCR-based monkeypox-specific assay developed by Thermo Fisher Scientific.

Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for retinal degenerative diseases, today announced that two executive team members will participate and present at the World Orphan Drug Congress, taking place July 11-13, at Hynes Center in Boston.

Samsung Biologics, the world’s leading contract development and manufacturing organization, published its second annual ESG Report, reflecting the company’s sustainability efforts in 2021 to address a wide range of environmental, social, and governance activities related to its business.

KAHR , a clinical-stage cancer immunotherapy company developing novel bi-functional fusion proteins, today announced the appointment of Jennifer Minai-Azary to its Board of Directors. The appointment is effective immediately.

MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm Labs” or the “Company”) has entered into a Share Purchase Agreement (the “Agreement”) with OneLife Botanicals PTY (“OneLife Botanicals”) for the sale of MediPharm Labs Australia Pty Ltd (“MPLA”), a wholly-owned subsidiary of the Company, for a minimum value of $6.9M AUD ($6.2M CAD).